Catafast

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Catafast

Quick Facts

Property Description
Active Ingredient Diclofenac potassium
Form Powder for oral solution, immediate-release tablets
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General Purpose Provides analgesic, anti-inflammatory, and antipyretic effects
Origin Synthetic Phenylacetic acid derivative

What Type of Medicine is Catafast and Its Classification?

Catafast is a trade name for a medicinal preparation whose active component is Diclofenac potassium, a substance officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This medicine is a synthetic compound, chemically recognized as a derivative of phenylacetic acid. As a single-component product (monotherapy), Catafast's identity is defined by its membership in the NSAID pharmacological class, which works to interrupt the biochemical pathways that contribute to inflammation and pain.

The classification as an NSAID signifies its core action is aimed at reducing the body's inflammatory response. Diclofenac acts primarily through the inhibition of cyclooxygenase enzymes, which are responsible for generating pro-inflammatory prostaglandins. This mechanism is clinically recognized for effectively targeting the root cause of acute inflammation, distinguishing it from simple pain relievers.


Active Ingredient, Formulation, and General Purpose

The active ingredient is Diclofenac potassium, which is specifically formulated for immediate-release to ensure rapid absorption following oral administration. Catafast is primarily available in dosage forms such as a powder for oral solution (sachet) or specialized immediate-release tablets.

This specific potassium salt formulation is key to its general therapeutic purpose: providing fast symptomatic relief. Diclofenac is recognized for its potent and rapid-onset anti-inflammatory and pain-relieving effects. The rapid absorption profile of the potassium salt formulation is intended to manage sudden, acute symptoms effectively, relying on its analgesic, anti-inflammatory, and antipyretic properties.

What side effects are possible with Catafast?

Possible side effects and safety information

The safety profile of Catafast (Diclofenac potassium) is formally classified based on the likelihood of occurrence, as defined by regulatory bodies like the EMA and FDA. Side effects are organized into frequency categories and grouped by the physiological system they affect.

Adverse Reaction Categories

Side effects that are classified as Common (ge 1/100 to <1/10 of patients) in official labeling primarily affect the gastrointestinal and nervous systems. These frequently reported effects include headache, dizziness, nausea, vomiting, diarrhea, dyspepsia (indigestion), abdominal pain, flatulence, and rash. Elevated liver enzymes (increased transaminases) are also classified as common.

Reactions classified as Rare (ge 1/10,000 to <1/1,000) or Very Rare (<1/10,000) include serious events such as hypersensitivity reactions, anaphylaxis, anemia, and psychiatric disorders.

Serious Adverse Reactions and Safety Constraints

Official regulatory documents emphasize the risk of serious adverse reactions, which include potentially fatal cardiovascular (CV) thrombotic events (such as myocardial infarction and stroke) and severe gastrointestinal (GI) adverse events (including bleeding, ulceration, and perforation of the stomach or intestines). These risks may occur early in treatment and tend to increase with dose and duration of use.

Serious reactions involving other organ systems include severe hepatotoxicity (liver failure) and life-threatening severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome. The medicine is formally contraindicated for use in patients with established cardiovascular disease, severe hepatic or renal failure, active GI ulcer/bleeding, or in the last trimester of pregnancy.

Overdose and Emergency Response

Overdose with Diclofenac potassium is officially documented to present with a spectrum of clinical manifestations. Initial signs often involve gastrointestinal disturbances, including nausea, vomiting, stomach pain, and diarrhea. Central Nervous System (CNS) effects are also common and include drowsiness, headache, dizziness, agitation, and ringing in the ears (tinnitus).

Regulatory documents identify severe and potentially life-threatening outcomes. These include the risk of acute renal failure, hepatic damage, and serious gastrointestinal complications such as severe internal bleeding, ulceration, and perforation. Severe CNS depression, including seizures and coma, is also cited in cases of massive overdose.

Due to the potential for these severe events, government guidance uniformly mandates that individuals seek immediate medical attention for any suspected overdose. Emergency medical services should be contacted, and any actions, such as inducing vomiting, must not be performed unless specifically instructed by poison control or a healthcare provider. Management is officially described as symptomatic and supportive, as regulatory documents state there is no specific antidote known. Furthermore, the elderly and patients with pre-existing renal or hepatic impairment are noted to be at a greater risk for serious overdose-related complications.

Therapeutic Uses of Catafast

Catafast is a form of Diclofenac often used in situations where quick symptomatic assistance is needed for acute painful and inflammatory conditions. Diclofenac is commonly used to help manage symptoms related to pain, tenderness, swelling, and stiffness associated with a range of conditions. It provides support that helps ease the overall symptom burden, particularly when symptoms may become more disruptive during flare-ups.

The medication is relevant in clinical settings marked by increased discomfort or tension, and its uses generally include the acute management of migraine attacks, severe primary dysmenorrhea (menstrual pain), pain from post-operative discomfort (e.g., after dental surgery), and inflammation associated with musculoskeletal conditions like sprains and flare-ups of chronic arthritis.

It is applied in scenarios where additional management of discomfort is required, such as following physical injury or during phases when symptoms become intense, and may assist with supporting functional stability.


Quick Fact: Symptomatic Support for Pain and Inflammation

Context Benefit
Symptom Profile Pain that may become intense; inflammation; swelling; fever
Primary Goal Support for symptoms associated with acute episodes
Key Scenarios Post-trauma, post-surgery, acute musculoskeletal flare-ups

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Catafast (Diclofenac Potassium)

Catafast is a non-steroidal anti-inflammatory drug (NSAID) primarily indicated for use in adults and adolescents aged 14 years and over. The 50 mg powder for oral solution formulation is not recommended for use in children under 14 years of age. Special medical caution is advised when prescribing to elderly patients, though no standard dose adjustment is typically required based on age alone.

Contraindications (Groups Who Must Not Use This Medicine)

Catafast is formally contraindicated in several specific populations due to serious health risks:

  • Patients with known hypersensitivity or allergy to diclofenac, aspirin, or any other NSAIDs, especially those with a history of asthma, urticaria, or acute rhinitis after taking these medicines.
  • Patients with active gastrointestinal bleeding, ulcer, or perforation, or a history of recurrent peptic ulcer/hemorrhage.
  • Patients with established congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
  • Use is forbidden in the setting of coronary artery bypass graft (CABG) surgery.
  • Patients with hepatic failure or severe renal failure.
  • Pregnancy is a contraindication during the last trimester.

Special Consideration: Use in patients with congestive heart failure (NYHA Class I) or significant cardiovascular risk factors should be limited to doses of le100 mg daily for extended treatment.

What should I know about interactions with other medicines?

Catafast (Diclofenac potassium) has officially documented interaction patterns primarily categorized by effects on bleeding risk, renal function, and metabolic clearance.

The use of Catafast is contraindicated for the treatment of peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery. It is also not generally recommended for co-administration with other non-steroidal anti-inflammatory drugs (NSAIDs) or analgesic doses of Aspirin.

The drug carries a significant risk of pharmacodynamic interaction related to hemostasis. Co-administration with Anticoagulants (such as Warfarin), Antiplatelet Agents, and Oral Corticosteroids synergistically increases the risk of serious gastrointestinal bleeding. Furthermore, it may diminish the antihypertensive and natriuretic effects of Diuretics, ACE Inhibitors, and ARBs. A specific population note highlights that in elderly or renally impaired patients, this combination may result in a deterioration of renal function.

In terms of pharmacokinetic interaction, Diclofenac is primarily metabolized by the CYP2C9 enzyme. Co-administration with CYP2C9 inhibitors (e.g., Voriconazole) significantly increases Diclofenac's systemic exposure, while CYP2C9 inducers may reduce its efficacy. Catafast also alters the clearance of other medicines, potentially enhancing the toxicity of Methotrexate and increasing the plasma concentrations of Lithium and Digoxin. For the powder formulation, administration must occur on an empty stomach, as food is documented to reduce peak plasma levels and effectiveness.

Mechanism of Action

Catafast (Diclofenac potassium) is defined by its precise pharmacodynamic mechanism, which involves intervening in specific biochemical pathways to modulate key physiological responses. The drug's action is defined by molecular interference that produces a cascade of downstream physiological changes.


Blocking the Prostaglandin Synthesis Cascade

The core mechanism of action begins at the molecular level with the non-selective competitive inhibition of the Cyclooxygenase (COX) enzymes (both COX-1 and COX-2). By blocking these enzymes, the active ingredient halts the production of prostaglandins, potent lipid-based mediators, thereby inhibiting the chemical mediators that contribute to inflammation and pyrexia.


️ Modulating Pain and Temperature Signals

The suppression of prostaglandin synthesis directly influences two vital physiological processes. Firstly, it reduces the over-sensitization of peripheral pain receptors (nociceptors), a process that helps to limit the magnitude of nociceptive signaling. Secondly, it decreases PGE2 concentration in the hypothalamus, which shifts the central thermostat set point, thereby permitting the body's natural heat dissipation mechanisms to operate.


Physiological Consequence of Pathway Interference

These molecular steps modify early biological events that lead to systemic physiological outcomes, resulting in pathway activity modulation. The consequence is a reduction in chemical mediators of inflammation, a decrease in peripheral nociceptor sensitization, and a shift in the hypothalamic thermoregulatory set point.

Dosage and Administration Information

How to Use Catafast

Catafast (Diclofenac potassium) is an immediate-release medicine whose usage is defined by administration rules concerning its route, dosage, frequency, and duration. This formulation is only intended for oral administration. The instructions mandate that therapy should use the lowest effective dose for the shortest possible duration to manage acute symptoms.


Administration Details and Dosing Principles

Instruction Entity Official Administration Principle
Route of Administration Oral only (Powder for oral solution or immediate-release tablets).
Preparation The powder must be fully dissolved by stirring in a glass of non-carbonated water and swallowed immediately.
Timing in Relation to Meals Consumption is directed to occur preferably before a meal to optimize rapid absorption.
Duration Constraint Intended for short-term use only, and treatment should not be prolonged beyond the acute need.

Standard Dosing and Frequency

For general acute pain, the daily dose typically ranges from 100 mg to 150 mg and is administered in divided doses. This means the total daily amount is usually split into two or three separate intakes. For acute episodes like a migraine attack, the initial dose is typically 50 mg. Subsequent doses may be taken at specified intervals (e.g., 4 to 6 hours) if required, but the total maximum daily dose must not be exceeded. In adolescents aged 14 and over, a dose of 50 mg to 100 mg daily is common, with a maximum of 150 mg per day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Catafast

The clinical evaluation of Diclofenac potassium (Catafast) was observed in research contexts for conditions characterized by acute, short-term pain and inflammatory states. The evidence base consists mainly of randomized controlled trials (RCTs) and systematic reviews, which help contextualize how the medicine was observed in specific study settings.


Evidence for Acute Pain Following Procedures (Postoperative Pain)

Research exploring short-term symptom changes was evaluated in settings involving pain following procedures, such as dental extractions or orthopedic surgeries. The evidence base for this use is composed of numerous short-term, single-dose, placebo-controlled clinical trials, which have been synthesized in systematic reviews. These studies primarily involved adults experiencing outcomes related to physical discomfort categorized as moderate to severe.

In these trials, researchers examined the change in pain reported by participants over several hours. Studies monitored the amount of time that passed until participants requested alternative pain relief. Studies reported how symptoms evolved in the observed populations related to their discomfort levels during the initial hours post-treatment. Limited information is available regarding the long-term outcomes and cumulative profile when the drug was observed in research exploring symptoms beyond the first few days of recovery.


Evidence for Acute Migraine Attacks

The research for the use of this medicine in migraine management was studied for episodes where patients were experiencing an acute attack. These studies explored outcomes describing episodic or acute changes specific to migraine, such as the achievement of pain-free status and the change in accompanying symptoms, typically measured at two hours after treatment.

Findings describe patterns observed in the studies related to the change in headache pain during the immediate post-treatment period. Long-term effects are not fully established for the repeated use of this medication over numerous migraine cycles. Additionally, data for pediatric or adolescent populations experiencing migraine remain insufficient compared to the adult evidence base.


Research Gaps and What Remains Unclear

A key research limitation is that long-term effects are not fully established because most efficacy studies focus on single-dose or very short-course treatment for conditions characterized by fluctuating or episodic manifestations. Furthermore, comparative evidence is lacking for certain indications, meaning direct, head-to-head trials against every other fast-acting NSAID are not available for all studied conditions. Research contributes to the broader evidence landscape, but these limitations mean the full scope of use and long-term profile are still subject to ongoing investigation.

Key Studies & References

  1. Diclofenac Drug Profile and Information
  2. Diclofenac Potassium Tablet, Film Coated (Diclofenac Potassium) Official FDA Monograph

Frequently Asked Questions (FAQ)

Common questions about Catafast (FAQ)

Q: How quickly should I expect Catafast to start working after taking it?

A: Catafast is an immediate-release formulation, and official product information indicates that measurable levels of the drug can be found in the blood plasma quickly. Peak concentrations in the blood are typically reached in approximately one hour in patients taking the medicine on an empty stomach.

Q: How long does the pain relief effect of one dose of Catafast usually last?

A: The terminal half-life of the unchanged drug is approximately two hours. This measurement describes how long the drug is present in the system, but the duration of the pain-relieving effect can vary among individuals.

Q: Is Catafast intended for short-term use only, or can it be used for long-term chronic conditions?

A: Regulatory documents state that this medicine is only recommended for short-term treatment. Use for prolonged periods is not recommended because the risk of serious side effects, particularly those affecting the heart and stomach, increases with both the duration of use and the dosage.

Q: Is it necessary to take Catafast with food to reduce the risk of side effects?

A: Official information states that taking Catafast with food can delay its absorption and reduce the concentration of the drug in the blood, which may lessen its effectiveness. To optimize the potential for rapid absorption and onset, the product information recommends it is preferably taken before a meal. Administration directions are provided by a healthcare professional.

Q: What kind of pain or inflammation is Catafast typically used to treat in post-operative care?

A: The drug is indicated for the short-term treatment of mild to moderate acute pain, inflammation, and swelling. Official documentation confirms its use in managing discomfort following certain procedures, such as dental or orthopedic surgery.

Q: Can Catafast be used at the same time as Tylenol (acetaminophen)?

A: Regulatory documents do not specifically list an interaction between Catafast and acetaminophen (Tylenol). However, it is important for patients to inform their healthcare provider about all medications, including over-the-counter pain relievers, to review for any potential risks.

Q: Is Catafast safe to use while breastfeeding?

A: Official information indicates that only a small amount of the active ingredient passes into breast milk. Decisions regarding the use of this medicine during breastfeeding are determined by a healthcare professional who evaluates the potential benefits and risks.

Q: Is Catafast considered a strong pain reliever, and for what type of pain is it typically used?

A: Catafast is indicated for the short-term management of mild to moderate acute pain, inflammation, and swelling, such as post-operative pain or acute migraine attacks. Its classification as a non-steroidal anti-inflammatory drug (NSAID) contributes to its anti-inflammatory and pain-relieving effects.

Q: Can Catafast affect blood pressure, and should people with high blood pressure be concerned?

A: Official warnings state that NSAIDs can potentially lead to new or worsen existing high blood pressure (hypertension). For this reason, close monitoring of patients with high blood pressure is advised when treatment is started or continued.

Q: What happens if I drink alcohol while taking Catafast?

A: Official safety information states that alcohol consumption should be avoided while taking this medicine. The combination may increase the risk of serious gastrointestinal side effects, including bleeding in the stomach or intestines.

Q: Does Catafast interact with any herbal supplements or vitamins?

A: It is necessary to inform a healthcare provider about all medications, including vitamins and herbal products, before starting treatment with Catafast. Regulatory documents note that caution is specifically advised when combining it with potassium salts, as this may increase blood potassium levels.

Q: Are there any antidepressants that interact with Catafast?

A: Regulatory documents include a caution for co-administration with Selective Serotonin Reuptake Inhibitors (SSRIs), which is a common class of antidepressant. Using Catafast alongside SSRIs increases the documented risk of gastrointestinal bleeding.

Q: What are the signs of liver problems that I should watch out for while taking Catafast?

A: Official documentation outlines potential signs of a serious liver problem. If these are noticed, it is necessary to contact a healthcare provider. These signs may include pain or tenderness in the upper abdomen, pale-colored stools, abnormally dark urine, or yellowing of the skin or eyes (jaundice).

Q: Is a severe skin rash a possible serious side effect of Catafast?

A: Yes, official warnings include the risk of severe, life-threatening skin reactions, such as Stevens-Johnson Syndrome (SJS). Patient information indicates that the drug should be discontinued at the first sign of a skin rash or hypersensitivity reaction.

Q: Can Catafast cause ringing in the ears (tinnitus)?

A: Yes, ringing in the ears, medically known as tinnitus, has been reported as a possible side effect in official product documentation.

Q: Does Catafast have an effect on a person's ability to drive or use machines?

A: Because side effects like dizziness, drowsiness, fatigue, or visual disturbances can occur with this class of medicine, regulatory bodies advise that patients who experience these effects should not operate machinery or drive.

Q: Is there a link between Catafast and fluid retention or swelling in the hands and feet?

A: Fluid retention, or edema (swelling), has been observed in some patients using NSAIDs, the class of medicine Catafast belongs to. Caution is advised for those with existing conditions related to fluid retention or heart failure.

Q: Is Catafast generally safe for people who have only cardiovascular risk factors like high cholesterol?

A: Official warnings indicate that patients with significant cardiovascular risk factors (including high blood pressure, high cholesterol, diabetes, and smoking) should be treated with the lowest effective dose for the shortest possible duration. This is especially relevant if treatment is expected to last longer than four weeks.

Q: What is the duration limit for using Catafast for acute pain?

A: The medicine is formally intended for short-term treatment only. All NSAIDs are advised to be used for the shortest duration necessary to manage acute symptoms, as this minimizes the potential risk for adverse cardiovascular events.

Q: Can Catafast mask the signs of an infection?

A: Yes, as an anti-inflammatory medicine, Catafast can reduce certain symptoms of an infection, such as fever, swelling, and pain. This effect could potentially delay the diagnosis or recognition of an underlying infection.

Q: Why must the dose of Catafast be individually adjusted by a doctor?

A: Dosing is individualized because official documents state that the risk of serious side effects, including cardiovascular events, increases with both the dose and the duration of use. Healthcare providers must determine the lowest effective dose needed to manage acute symptoms for the shortest time.

Q: Is it true that Catafast may affect fertility?

A: Official product information notes that the use of this medicine may potentially impair female fertility. It is not recommended for use in women who are actively trying to conceive. If a woman has difficulty conceiving, the discontinuation of the drug is noted as a consideration.

Q: Can Catafast cause changes in vision or blurry eyesight?

A: Yes, visual disturbances and blurred vision have been reported as possible side effects. Regulatory documents state that patients who experience these visual changes should avoid driving or operating machinery.

Q: What are the key points to discuss with a doctor before starting Catafast?

A: Key areas to discuss with a doctor before starting treatment, based on regulatory warnings, include any history of heart problems, stomach or intestinal bleeding, high blood pressure, asthma, and the use of other medicines. This includes blood thinners, blood pressure medicines, or any other pain relievers.

Q: Does Catafast have any effect on blood sugar levels?

A: Patients with diabetes are listed among those with cardiovascular risk factors who require cautious treatment. However, regulatory documents do not provide an explicit statement confirming if the drug directly alters blood sugar levels.

Q: Is Catafast the same as Cataflam, or are they different drugs?

A: Catafast and Cataflam are both brand names for the active pharmaceutical ingredient diclofenac potassium. They share the same active ingredient and belong to the same pharmacological class.

Q: Does Catafast interact with common blood pressure medications?

A: Yes, regulatory documents warn that Catafast may reduce the blood pressure lowering effects of certain common blood pressure medicines, including Diuretics, ACE Inhibitors, and Angiotensin Receptor Blockers (ARBs). Caution is advised and monitoring is recommended when this combination is used.

Q: Does Catafast require blood monitoring during prolonged treatment?

A: Yes, for patients who are receiving long-term treatment, official guidelines recommend regular monitoring. This precautionary measure includes checking blood counts, as well as kidney (renal) and liver (hepatic) function.

How should Catafast be stored and disposed of?

How to Store and Dispose of Catafast

The storage and disposal of Catafast (diclofenac potassium powder for oral solution) must comply strictly with official regulatory requirements to maintain product integrity and ensure safety.

Storage Requirements

  • Temperature: The product must be stored at a Controlled Room Temperature, typically below 30 C. Excessive heat and freezing must be avoided.
  • Protection: The powder should be kept in its original package (sachet) to protect it from moisture and light.
  • Reconstituted Solution: Once mixed with water, the oral solution must be swallowed immediately and cannot be stored for later use.
  • Child Safety: The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Catafast must be disposed of according to local requirements for pharmaceutical waste. The product must not be thrown into household waste or poured into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Catafast found in:

A-Z Index: